Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Novavax News

Aktie
WKN:  A2PKMZ ISIN:  US6700024010 US-Symbol:  NVAX Branche:  Biotechnologie Land:  USA
8,835 $
+0,185 $
+2,14%
7,5103 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
942,83 Mio. €
Streubesitz
29,59%
KGV
3,13
Nachhaltigkeits-Score
25 %
Index-Zuordnung
-

Novavax News

30.03.26 - PR Newswire
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development PR Newswire
27.02.26 wallstreetONLINE Redaktion
FOMO an der Wall Street: Novavax meldet überraschenden Gewinn – Aktie schießt zweistellig hoch
Ein Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-​Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält dieses Momentum?Novavax hat mit ...
26.02.26 - PR Newswire
Novavax to Participate in Upcoming Investor Conferences
Novavax to Participate in Upcoming Investor Conferences PR Newswire
26.02.26 - PR Newswire
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights PR Newswire
23.02.26 Handelsblatt
Cagrisema: „Worst-Case-Szenario“ für Novo Nordisk – Aktie fällt bis zu 16 Prozent
Mit dem Diätmittel Cagrisema hofft der dänische Pharmakonzern auf Milliardenumsätze. In einer neuen Vergleichsstudie enttäuscht der Wirkstoff aber. Die Aktionäre reagieren ...
19.02.26 - PR Newswire
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 PR Newswire
20.01.26 - PR Newswire
Novavax Announces Entering into a License Agreement with Pfizer
Novavax Announces Entering into a License Agreement with Pfizer PR Newswire
07.01.26 - PR Newswire
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
12.11.25 - PR Newswire
Novavax to Participate in Jefferies London Healthcare Conference
Novavax to Participate in Jefferies London Healthcare Conference PR Newswire
06.11.25 - PR Newswire
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
04.11.25 - PR Newswire
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment PR Newswire
30.10.25 - PR Newswire
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire
22.10.25 - PR Newswire
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy PR Newswire
07.10.25 - PR Newswire
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment PR Newswire
30.09.25 - PR Newswire
Novavax Announces Progress on Sanofi Agreement
Novavax Announces Progress on Sanofi Agreement PR Newswire
04.09.25 - PR Newswire
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment PR Newswire
03.09.25 - PR Newswire
Novavax to Participate in the Cantor Global Healthcare Conference
Novavax to Participate in the Cantor Global Healthcare Conference PR Newswire
27.08.25 - PR Newswire
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. PR Newswire
22.08.25 wallstreetONLINE Redaktion
Milliarden-Verlustgefahr: Nach zweistelligem Absturz: Warum Novavax-Investoren weiter zittern müssen
Novavax steht unter massivem Druck: Ein Analysten-​Downgrade, neue Milliarden-​Schulden und Zweifel an der Impfstoff-​Zukunft haben die Aktie zweistellig abstürzen lassen. ...
21.08.25 - PR Newswire
Novavax Announces Convertible Debt Refinancing
Novavax Announces Convertible Debt Refinancing PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »